These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

549 related articles for article (PubMed ID: 26908832)

  • 1. Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: a position statement on behalf of the ERA-EDTA Working Groups on Inherited Kidney Disorders and European Renal Best Practice.
    Gansevoort RT; Arici M; Benzing T; Birn H; Capasso G; Covic A; Devuyst O; Drechsler C; Eckardt KU; Emma F; Knebelmann B; Le Meur Y; Massy ZA; Ong AC; Ortiz A; Schaefer F; Torra R; Vanholder R; Więcek A; Zoccali C; Van Biesen W
    Nephrol Dial Transplant; 2016 Mar; 31(3):337-48. PubMed ID: 26908832
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An update on the use of tolvaptan for autosomal dominant polycystic kidney disease: consensus statement on behalf of the ERA Working Group on Inherited Kidney Disorders, the European Rare Kidney Disease Reference Network and Polycystic Kidney Disease International.
    Müller RU; Messchendorp AL; Birn H; Capasso G; Cornec-Le Gall E; Devuyst O; van Eerde A; Guirchoun P; Harris T; Hoorn EJ; Knoers NVAM; Korst U; Mekahli D; Le Meur Y; Nijenhuis T; Ong ACM; Sayer JA; Schaefer F; Servais A; Tesar V; Torra R; Walsh SB; Gansevoort RT
    Nephrol Dial Transplant; 2022 Apr; 37(5):825-839. PubMed ID: 35134221
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rationale and design of the TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and its Outcomes) 3-4 Study.
    Torres VE; Meijer E; Bae KT; Chapman AB; Devuyst O; Gansevoort RT; Grantham JJ; Higashihara E; Perrone RD; Krasa HB; Ouyang JJ; Czerwiec FS
    Am J Kidney Dis; 2011 May; 57(5):692-9. PubMed ID: 21333426
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tolvaptan: A Review in Autosomal Dominant Polycystic Kidney Disease.
    Blair HA; Keating GM
    Drugs; 2015 Oct; 75(15):1797-806. PubMed ID: 26407729
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Review of tolvaptan for autosomal dominant polycystic kidney disease.
    Baur BP; Meaney CJ
    Pharmacotherapy; 2014 Jun; 34(6):605-16. PubMed ID: 24706579
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Autosomal Dominant Polycystic Kidney Disease: Clinical Assessment of Rapid Progression.
    Furlano M; Loscos I; Martí T; Bullich G; Ayasreh N; Rius A; Roca L; Ballarín J; Ars E; Torra R
    Am J Nephrol; 2018; 48(4):308-317. PubMed ID: 30347391
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Short-term Effects of Tolvaptan in Individuals With Autosomal Dominant Polycystic Kidney Disease at Various Levels of Kidney Function.
    Boertien WE; Meijer E; de Jong PE; ter Horst GJ; Renken RJ; van der Jagt EJ; Kappert P; Ouyang J; Engels GE; van Oeveren W; Struck J; Czerwiec FS; Oberdhan D; Krasa HB; Gansevoort RT
    Am J Kidney Dis; 2015 Jun; 65(6):833-41. PubMed ID: 25600953
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease by CKD Stage: Results from the TEMPO 3:4 Trial.
    Torres VE; Higashihara E; Devuyst O; Chapman AB; Gansevoort RT; Grantham JJ; Perrone RD; Ouyang J; Blais JD; Czerwiec FS;
    Clin J Am Soc Nephrol; 2016 May; 11(5):803-811. PubMed ID: 26912543
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expanding the role of vasopressin antagonism in polycystic kidney diseases: From adults to children?
    Janssens P; Weydert C; De Rechter S; Wissing KM; Liebau MC; Mekahli D
    Pediatr Nephrol; 2018 Mar; 33(3):395-408. PubMed ID: 28455745
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Urine Osmolality, Response to Tolvaptan, and Outcome in Autosomal Dominant Polycystic Kidney Disease: Results from the TEMPO 3:4 Trial.
    Devuyst O; Chapman AB; Gansevoort RT; Higashihara E; Perrone RD; Torres VE; Blais JD; Zhou W; Ouyang J; Czerwiec FS
    J Am Soc Nephrol; 2017 May; 28(5):1592-1602. PubMed ID: 27920153
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An update on tolvaptan for autosomal dominant polycystic kidney disease.
    Poch E; Rodas L; Blasco M; Molina A; Quintana L
    Drugs Today (Barc); 2018 Sep; 54(9):519-533. PubMed ID: 30303493
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Short-term renal hemodynamic effects of tolvaptan in subjects with autosomal dominant polycystic kidney disease at various stages of chronic kidney disease.
    Boertien WE; Meijer E; de Jong PE; Bakker SJ; Czerwiec FS; Struck J; Oberdhan D; Shoaf SE; Krasa HB; Gansevoort RT
    Kidney Int; 2013 Dec; 84(6):1278-86. PubMed ID: 23903369
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Treatment of autosomal dominant polycystic kidney disease (ADPKD) - Tolvaptan].
    Cirillo M
    G Ital Nefrol; 2016; 33(5):. PubMed ID: 27796022
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Tolvaptan, a vasopressin V
    Yamada Y; Fujiki H; Mizuguchi H; Takeshita Y; Hattori K; Ohmoto K; Aihara M; Nagano K; Isakari Y; Yamamoto M; Yamamura Y
    Nihon Yakurigaku Zasshi; 2022; 157(4):254-260. PubMed ID: 35781456
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tolvaptan and Kidney Pain in Patients With Autosomal Dominant Polycystic Kidney Disease: Secondary Analysis From a Randomized Controlled Trial.
    Casteleijn NF; Blais JD; Chapman AB; Czerwiec FS; Devuyst O; Higashihara E; Leliveld AM; Ouyang J; Perrone RD; Torres VE; Gansevoort RT;
    Am J Kidney Dis; 2017 Feb; 69(2):210-219. PubMed ID: 27856088
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Urinary EGF Receptor Ligand Excretion in Patients with Autosomal Dominant Polycystic Kidney Disease and Response to Tolvaptan.
    Harskamp LR; Gansevoort RT; Boertien WE; van Oeveren W; Engels GE; van Goor H; Meijer E
    Clin J Am Soc Nephrol; 2015 Oct; 10(10):1749-56. PubMed ID: 26231191
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Practical Guide for Treatment of Rapidly Progressive ADPKD with Tolvaptan.
    Chebib FT; Perrone RD; Chapman AB; Dahl NK; Harris PC; Mrug M; Mustafa RA; Rastogi A; Watnick T; Yu ASL; Torres VE
    J Am Soc Nephrol; 2018 Oct; 29(10):2458-2470. PubMed ID: 30228150
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Short-term effects of tolvaptan on renal function and volume in patients with autosomal dominant polycystic kidney disease.
    Irazabal MV; Torres VE; Hogan MC; Glockner J; King BF; Ofstie TG; Krasa HB; Ouyang J; Czerwiec FS
    Kidney Int; 2011 Aug; 80(3):295-301. PubMed ID: 21544064
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modelling the long-term benefits of tolvaptan therapy on renal function decline in autosomal dominant polycystic kidney disease: an exploratory analysis using the ADPKD outcomes model.
    Bennett H; McEwan P; Hamilton K; O'Reilly K
    BMC Nephrol; 2019 Apr; 20(1):136. PubMed ID: 31014270
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessing Risk of Rapid Progression in Autosomal Dominant Polycystic Kidney Disease and Special Considerations for Disease-Modifying Therapy.
    Chebib FT; Torres VE
    Am J Kidney Dis; 2021 Aug; 78(2):282-292. PubMed ID: 33705818
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.